A comparison of two methods for estimating refill adherence to statins in Sweden: The RARE project

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 10, 2011, Pages 1073-1079

  Lesén, Eva ^a   Sandström, Tatiana Z ^a   Carlsten, Anders ^b   Jönsson, Anna K ^a,c   Mårdby, Ann Charlotte ^d   Sundell, Karolina Andersson ^a  

^a NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^b MEDICAL PRODUCTS AGENCY   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Drug utilisation; Medication adherence; Statins; Swedish Prescribed Drug Register

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CONTINUOUS MEASURE OF MEDICATION ACQUISITION; DEATH; DRUG UTILIZATION; FEMALE; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; MALE; MATHEMATICAL ANALYSIS; MAXIMUM GAP METHOD; MIGRATION; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; REFILL ADHERENCE; SENSITIVITY ANALYSIS; SWEDEN;

ADULT; AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PRESCRIPTIONS; SENSITIVITY AND SPECIFICITY; STATISTICS AS TOPIC; SWEDEN; YOUNG ADULT;

EID: 80053247431     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2204     Document Type: Article

References (25)

1. World Health Organization. Adherence to long-term therapies: Evidence for action. Geneva; 2003.
2. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-497.
3. Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009; 15: 728-740.
4. Hess LM, Raebel MA, Conner DA, et al. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006; 40: 1280-1288.
5. Van Wijk BL, Klungel OH, Heerdink ER, et al. Refill persistence with chronic medication assessed from a pharmacy database was influenced by method of calculation. J Clin Epidemiol 2006; 59: 11-17.
6. Vink NM, Klungel OH, Stolk RP, et al. Comparison of various measures for assessing medication refill adherence using prescription data. Pharmacoepidemiol Drug Saf 2009; 18: 159-165.
7. Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006; 15: 565-574.
8. Hudson M, Rahme E, Richard H, et al. Comparison of measures of medication persistency using a prescription drug database. Am Heart J 2007; 153: 59-65.
9. Karve S, Cleves MA, Helm M, et al. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care 2008; 46: 1125-1133.
10. Ong M, Catalano R, Hartig T. A time-series analysis of the effect of increased copayments on the prescription of antidepressants, anxiolytics, and sedatives in Sweden from 1990 to 1999. Clin Ther 2003; 25: 1262-1275.
11. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA 2004; 291: 2344-2350.
12. Wagner AK, Soumerai SB, Zhang F, et al. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002; 27: 299-309.
13. McManus P, Donnelly N, Henry D, et al. Prescription drug utilization following patient co-payment changes in Australia. Pharmacoepidemiol Drug Saf 1996; 5: 385-392.
14. Martikainen JE, Saastamoinen LK, Korhonen MJ, et al. Impact of restricted reimbursement on the use of statins in Finland: a register-based study. Med Care 2010; 48: 761-766.
15. Larsen J, Andersen M, Kragstrup J, et al. High persistence of statin use in a Danish population: compliance study 1993-1998. Br J Clin Pharmacol 2002; 53: 375-378.
16. Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug Register--opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16: 726-735.
17. Act (2002:160) on Pharmaceutical Benefits, etc. In: SFS; 2002.
18. Karve S, Cleves MA, Helm M, et al. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009; 25: 2303-2310.
19. Wei L, Wang J, Thompson P, et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002; 88: 229-233.
20. Chan DC, Shrank WH, Cutler D, et al. Patient, physician, and payment predictors of statin adherence. Med Care 2010; 48: 196-202.
21. Ye X, Gross CR, Schommer J, et al. Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study. Clin Ther 2007; 29: 2748-2757.
22. Caspard H, Chan AK, Walker AM. Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3years after treatment initiation in health maintenance organization enrollees with dyslipidemia. Clin Ther 2005; 27: 1639-1646.
23. Ellis JJ, Erickson SR, Stevenson JG, et al. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 2004; 19: 638-645.
24. Lachaine J, Rinfret S, Merikle EP, et al. Persistence and adherence to cholesterol lowering agents: evidence from Regie de l'Assurance Maladie du Quebec data. Am Heart J 2006; 152: 164-169.
25. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288: 462-467.